Department of Pharmacology, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Gastroenterology. 2013 Nov;145(5):1064-1075.e11. doi: 10.1053/j.gastro.2013.07.033. Epub 2013 Jul 25.
BACKGROUND & AIMS: Loss of the tumor suppressor SMAD4 correlates with progression of colorectal cancer (CRC). In mice, colon tumors that express CCL9 recruit CCR1(+) myeloid cells, which facilitate tumor invasion and metastasis by secreting matrix metalloproteinase 9.
We used human CRC cell lines to investigate the ability of SMAD4 to regulate expression of CCL15, a human ortholog of mouse CCL9. We used immunohistochemistry to compare levels of CCL15 and other proteins in 141 samples of human liver metastases.
In human CRC cell lines, knockdown of SMAD4 increased CCL15 expression, and overexpression of SMAD4 decreased it. SMAD4 bound directly to the promoter region of the CCL15 gene to negatively regulate its expression; transforming growth factor-β increased binding of SMAD4 to the CCL15 promoter and transcriptional repression. In livers of nude mice, SMAD4-deficient human CRC cells up-regulated CCL15 to recruit CCR1(+) cells and promote metastasis. In human tumor samples, there was a strong inverse correlation between levels of CCL15 and SMAD4; metastases that expressed CCL15 contained 3-fold more CCR1(+) cells than those without CCL15. Patients with CCL15-expressing metastases had significantly shorter times of disease-free survival than those with CCL15-negative metastases. CCR1(+) cells in the metastases expressed the myeloid cell markers CD11b and myeloperoxidase, and also matrix metalloproteinase 9.
In human CRC cells, loss of SMAD4 leads to up-regulation of CCL15 expression. Human liver metastases that express CCL15 contain higher numbers CCR1(+) cells; patients with these metastases have shorter times of disease-free survival. Reagents designed to block CCL15 recruitment of CCR1(+) cells could prevent metastasis of CRC to liver.
抑癌基因 SMAD4 的缺失与结直肠癌(CRC)的进展相关。在小鼠中,表达 CCL9 的结肠肿瘤招募 CCR1(+)髓样细胞,这些细胞通过分泌基质金属蛋白酶 9 促进肿瘤侵袭和转移。
我们使用人 CRC 细胞系研究 SMAD4 调节人同源物 CCL15(小鼠 CCL9 的人同源物)表达的能力。我们使用免疫组织化学比较了 141 个人类肝转移样本中 CCL15 和其他蛋白质的水平。
在人 CRC 细胞系中,SMAD4 的敲低增加了 CCL15 的表达,而过表达 SMAD4 则降低了它的表达。SMAD4 直接结合 CCL15 基因的启动子区域,负调控其表达;转化生长因子-β增加了 SMAD4 与 CCL15 启动子的结合和转录抑制。在裸鼠的肝脏中,SMAD4 缺陷的人 CRC 细胞上调 CCL15,招募 CCR1(+)细胞并促进转移。在人类肿瘤样本中,CCL15 的水平与 SMAD4 呈强烈负相关;表达 CCL15 的转移瘤中 CCR1(+)细胞的数量比不表达 CCL15 的转移瘤多 3 倍。表达 CCL15 转移瘤的患者无病生存期明显短于不表达 CCL15 的转移瘤患者。转移瘤中的 CCR1(+)细胞表达髓样细胞标志物 CD11b 和髓过氧化物酶,也表达基质金属蛋白酶 9。
在人 CRC 细胞中,SMAD4 的缺失导致 CCL15 表达上调。表达 CCL15 的人肝转移瘤含有更多数量的 CCR1(+)细胞;这些转移瘤患者无病生存期较短。设计用于阻断 CCL15 募集 CCR1(+)细胞的试剂可防止 CRC 向肝脏转移。